|
NEDD8
|
OGG_3000004738 |
|
|
NEDD9
|
OGG_3000004739 |
|
|
ACE 1 inhibitor therapy
|
MAXO_0000655 |
[Use of a drug that inhibits angiotensin-converting enzyme (ACE) 1, an enzyme that catalyzes the conversion of angiotensin I to angiotensin II.] |
|
ACE inhibitor therapy
|
MAXO_0000652 |
[Use of a drug that inhibits angiotensin-converting enzyme (ACE), an enzyme that catalyzes the conversion of angiotensin I to angiotensin II. Inhibition of ACE results in a reduction in angiotensin II and angiotensin II-induced aldosterone secretion, causing vasodilation and natriuresis.] |
|
ACE 2 inhibitor therapy
|
MAXO_0000656 |
[Use of a drug that inhibits angiotensin-converting enzyme (ACE) 2, an enzyme that catalyzes the conversion of angiotensin I to angiotensin II.] |
|
phosphatidylcholine
|
CHEBI_64482 |
[A glycerophosphocholine that is glycero-3-phosphocholine bearing two acyl substituents at positions 1 and 2.] |
|
CCR3
|
OGG_3000001232 |
|
|
tolmetin
|
CHEBI_71941 |
[A monocarboxylic acid that is (1-methylpyrrol-2-yl)acetic acid substituted at position 5 on the pyrrole ring by a 4-methylbenzoyl group. Used in the form of its sodium salt dihydrate as a nonselective nonsteroidal anti-inflammatory drug.] |
|
CCR4
|
OGG_3000001233 |
|
|
gender
|
GECKO_0000060 |
[An organismal quality inhering in a bearer by virtue of the bearer's preference towards a range of characteristics pertaining to, and differentiating between, masculinity and femininity.] |
|
CCR5
|
OGG_3000001234 |
|
|
RHOA
|
OGG_3000000387 |
|
|
UNC13A
|
OGG_3000023025 |
|
|
CCR1
|
OGG_3000001230 |
|
|
Glucose-6-Phosphate
|
DRON_00817881 |
|
|
CCR6
|
OGG_3000001235 |
|
|
CCR7
|
OGG_3000001236 |
|
|
IDE
|
OGG_3000003416 |
|
|
CCR8
|
OGG_3000001237 |
|
|
ZCWPW1
|
OGG_3000055063 |
|
